The science driving precision medicine — specific therapies developed for narrowly defined groups of patients, often using genetic or molecular profiling — is advancing rapidly. But science is not enough. Exploiting these opportunities requires significant capital. That’s because research to develop a new treatment and bring a new drug to market is extremely expensive, and conventional methods for obtaining funding aren’t adequate. Consequently, new funding models are required in which disease-focused nonprofit research foundations play a central role in raising capital and mobilizing an ecosystem focused on controlling and curing a disease.

Read More